In a recent interview, executives from two early-stage biopharma companies said that off-the-shelf approach is the only way to drive down the cost of novel cell and gene therapies like CAR-T.
Emflaza, the brand name for deflazacort, has never been approved for sale in the United States, but the steroid has been sold for decades in other countries — at much lower prices
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.